Enhancing surgery for breast cancer patients.
Hall-Perrine Cancer Center at Mercy Medical Center is the first hospital in Iowa to use MarginProbe® technology during early-stage breast lumpectomy surgeries. Surgeons performing breast cancer surgery at Mercy will be able to use the probe on removed cancerous tissue to detect whether there is any remaining cancer surrounding a removed lump. The MarginProbe System delivers clarity in real-time, reducing doubt and the likelihood of a second surgery.
Early Stage Breast Cancer Facts
- 285,000 women are diagnosed with breast cancer in the U.S. each year.
- Over half are for early-stage cancer.
- In 60 to 75% of breast cancer cases, patients will undergo a lumpectomy vs. mastectomy.
- 30 to 60% of women undergo repeat surgery following a lumpectomy.
Here’s how it works:
Having a “clean margin” around the site of the cancer is important to increase the likelihood of a successful outcome through that course of treatment. Therefore, all cancer cells must be fully eliminated at the edge of the removed tissue.
During surgery, the surgeon uses a probe to test the margins of removed tissue. Within minutes, the MarginProbe System provides real-time, detailed information indicating whether cancer remains at the edge of the removed tissue. This aids the surgeon in deciding whether to remove additional tissue or to complete the lumpectomy procedure and close the incision.
MarginProbe detects cancer by assessing the electromagnetic response of tissue. The system allows the surgeon to probe suspect tissue, capturing microscopic differences in electromagnetic properties. The system characterizes the tissue’s electromagnetic signature and then compares those responses to an internal database of known signatures in healthy and cancerous tissues.
Benefits of MarginProbe:
- Is three times more effective in identifying “cancer on the margin” during lumpectomy than traditional, intra-operative methods.
- Increases probability of having clean margins.
- Reduces patient anxiety.
- Reduces the likelihood of a second surgery.
"This is remarkable technology that will enhance the surgical care we’re delivering to our patients. Studies have shown that reoperation rates are significantly decreased with the aid of this tool. I’m certain patients will find it to be of great benefit to their care here at Mercy."
-- Vincent Reid, MD
Medical Director, Hall-Perrine Cancer Center
Dr. Reid led the charge to bring MarginProbe to the community. He is the only fellowship-trained oncologic surgeon in Cedar Rapids.